United StatesThe FDA recently approved a new pancreatic cancer drug called Rasonque, developed by Revolution Medicines, which has shown potential to nearly double median overall survival rates for patients. However, patients who were relying on the drug's expanded access program, intended for those who couldn't wait for formal approval, now face significant barriers to obtaining the treatment. Once the drug was officially approved, the expanded access program was abruptly closed, leaving many patients in limbo. Insurance companies typically take weeks or months to determine coverage for newly approved medications, creating a gap during which critically ill patients may lose access to life-saving treatments. Some patients have encountered confusion or outright denials from insurers, citing incorrect reasons such as the drug not being 'properly listed' with the FDA. In some cases, these issues have been resolved after public scrutiny, but others remain unresolved.
Bias read (Center): The article discusses a medical development and its impact on patient access, focusing on healthcare challenges rather than political debates, policies, or partisan issues. There is no clear ideological framing or bias in the presentation of facts.
